MIMEDX Announces Third Quarter 2021 Operating and Financial Results
November 02, 2021 16:50 ET
|
MiMedx Group, Inc
Third Quarter Net Sales of $63.1 Million Versus $64.3 Million in 3Q20 Adjusted Net Sales of $62.8 Million Include a 13% Increase in Core Portfolio Sales Versus 3Q20 Year-to-Date Adjusted Net Sales...
MIMEDX to Participate at Upcoming Investor Conferences
November 02, 2021 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative...
Two New Studies Demonstrate in vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) to Prevent Pathological Processes Underlying Osteoarthritis (OA) and Tendinopathy
November 01, 2021 08:30 ET
|
MiMedx Group, Inc
Data Show mdHACM Mitigates Effects of Inflammatory-Induced Degeneration in Chondrocytes, the Primary Cell Type in Cartilage; May Mitigate Vessel Formation and Repair MARIETTA, Ga., Nov. 01, 2021 ...
MIMEDX to Host Third Quarter 2021 Operating and Financial Results Conference Call on November 3
October 20, 2021 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Oct. 20, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative...
MIMEDX to Host Virtual Investor Day on December 7, 2021
October 14, 2021 16:05 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative...
MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology
September 13, 2021 06:30 ET
|
MiMedx Group, Inc
Phase 2B Knee Osteoarthritis (KOA) Study Top-line Interim Results Demonstrate Varied Efficacy Signals between Patient Cohorts Company to Pursue Phase 3 KOA Confirmatory Studies Initial Review of...
MIMEDX Announces Effectiveness of Shelf Registration Statement
September 08, 2021 07:30 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Sept. 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative...
MIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative...
MIMEDX Announces Filing of Shelf Registration Statement with Securities and Exchange Commission
August 27, 2021 09:00 ET
|
MiMedx Group, Inc
S-3 Eligibility Enabled by Accomplishment of Multiple Financial Milestones MARIETTA, Ga., Aug. 27, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an...
Medicare Data: Significant Reductions in Amputations, Emergency Visits, and Hospital Readmissions Associated with Advanced Treatment Using Skin Substitute Products for Lower Extremity Diabetic Ulcers (LEDUs)
August 17, 2021 08:30 ET
|
MiMedx Group, Inc
New study shows advanced treatment (AT) for management of LEDUs among Medicare beneficiaries is associated with significant reductions in major and minor amputation, emergency department (ED) use, and...